Erythropoietin (Recombinant Human Erythropoietin)

Indications
 Parenteral
Anaemia of chronic renal failure
Adult: As epoetin alfa: Initially, 50 U/kg SC/IV 3 times wkly for predialysis and haemodialysis patients and 50 U/kg twice wkly for peritoneal dialysis patients, may increase according to response in steps of 25 U/kg 3 times wkly at 4 wkly intervals.
Child: As epoetin alfa: Initially, 50 U/kg 3 times wkly. May increase dose at 4 wkly intervals in increments of 25 U/kg 3 times wkly until a target haemoglobin concentration of 9.5-11 g/100 mL is reached. Usual maintenance dose: <10 kg: 225-450 U/kg/wk; 10-30 kg: 180-450 U/kg/wk and >30 kg: 90-300 U/kg/wk.
Parenteral
Anaemia in zidovudine-treated HIV-infected patients
Adult: As epoetin alfa: Initially, 100 U/kg SC/IV thrice wkly for 8 wk; increase every 4-8 wk by 50-100 U/kg according to response. Max: 300 U/kg thrice wkly.
Subcutaneous
Anaemia related to non-myeloid malignant disease chemotherapy
Adult: As epoetin alfa or zeta: Initially, 150 U/kg 3 times wkly. Dose may be increased at 4-8 wk intervals to 300 U/kg 3 times wkly. Stop treatment if response is still inadequate after 4 wk of treatment using this higher dose.
Intravenous
Increase yield of autologous blood
Adult: As epoetin alfa or zeta: 600 U/kg over 2 minutes twice wkly for 3 wk before surgery; in conjunction with iron, folate and B12 supplementation.
Contraindications
 Uncontrolled hypertension, hypersensitivity to mammalian cell products and human albumin.
Warnings / Precautions
 Chronic renal failure, ischaemic heart diseases, hypertension, pregnancy, seizures, liver dysfunction, lactation.
Adverse Reactions
 Hypertension, myalgia, arthralgia, flu-like syndrome, rashes and urticaria.
Potentially Fatal: Hypertensive crisis with encephalopathy-like symptoms e.g. headache, confusion, generalised seizures. Thrombosis.
Drug Interactions
 Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis.
See Below for More erythropoietin Drug Interactions
Mechanism of Actions
 Erythropoietin regulates erythropoiesis by stimulating the differentiation and proliferation of erythroid precursors, stimulating the release of reticulocytes into the circulation, and synthesis of cellular haemoglobin. Recombinant human erythropoietin is available as epoetin alfa and epoetin beta which are used in the management of anaemias associated with CRF, cancer chemotherapy and anti-AIDS drug zidovudine.
Storage Conditions
 Intravenous: Refrigerate at 2-8°C. Do not freeze. Parenteral: Refrigerate at 2-8°C. Do not freeze. Subcutaneous: Refrigerate at 2-8°C. Do not freeze.
ATC Classification
 B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations.
Storage
 Intravenous: Refrigerate at 2-8°C. Do not freeze. Parenteral: Refrigerate at 2-8°C. Do not freeze. Subcutaneous: Refrigerate at 2-8°C. Do not freeze.
Available As
  • Erythropoietin (Recombinant Human Erythropoietin) 1000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 10000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 2000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 20000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 3000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 4000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 40000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 5000 iu
  • Erythropoietin (Recombinant Human Erythropoietin) 6000 iu

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Erythropoietin (Recombinant Human Erythropoietin)


    Erythropoietin (Recombinant Human Erythropoietin) Containing Brands

    We are Developing Our database, More results coming soon.

    Erythropoietin (Recombinant Human Erythropoietin) is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Erythropoietin (Recombinant Human Erythropoietin)

    We are Developing Our database, More results coming soon.